774 related articles for article (PubMed ID: 34305135)
1. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
Parums DV
Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease: Recent treatment strategies.
Vaz M; Silvestre S
Eur J Pharmacol; 2020 Nov; 887():173554. PubMed ID: 32941929
[TBL] [Abstract][Full Text] [Related]
3. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro S; Valeri A; Mazzon E
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
[TBL] [Abstract][Full Text] [Related]
4. Aducanumab: The first targeted Alzheimer's therapy.
Yang P; Sun F
Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
[TBL] [Abstract][Full Text] [Related]
5. Aducanumab: First Approval.
Dhillon S
Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
[TBL] [Abstract][Full Text] [Related]
6. A Review of the Current Status of Disease-Modifying Therapies and Prevention of Alzheimer's Disease.
Parums DV
Med Sci Monit; 2024 May; 30():e945091. PubMed ID: 38736218
[TBL] [Abstract][Full Text] [Related]
7. Aducanumab for Alzheimer's disease: A regulatory perspective.
Nisticò R; Borg JJ
Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
[TBL] [Abstract][Full Text] [Related]
8. Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.
Golde TE
Neurotherapeutics; 2022 Jan; 19(1):209-227. PubMed ID: 35229269
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?
Villain N
Rev Neurol (Paris); 2022 May; 178(5):437-440. PubMed ID: 35489824
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
11. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies.
Zetterberg H; Bendlin BB
Mol Psychiatry; 2021 Jan; 26(1):296-308. PubMed ID: 32251378
[TBL] [Abstract][Full Text] [Related]
13. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
[TBL] [Abstract][Full Text] [Related]
14. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
[TBL] [Abstract][Full Text] [Related]
15. [Aducanumab and Alzheimer's disease: a critical reflection.].
Vanacore N; Blasimme A; Canevelli M
Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond.
Song C; Shi J; Zhang P; Zhang Y; Xu J; Zhao L; Zhang R; Wang H; Chen H
Transl Neurodegener; 2022 Mar; 11(1):18. PubMed ID: 35300725
[TBL] [Abstract][Full Text] [Related]
17. Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update.
Yadollahikhales G; Rojas JC
Neurotherapeutics; 2023 Jul; 20(4):914-931. PubMed ID: 37490245
[TBL] [Abstract][Full Text] [Related]
18. New Treatment Aimed at Preventing Alzheimer's Dementia.
Kverno K
J Psychosoc Nurs Ment Health Serv; 2022 May; 60(5):11-14. PubMed ID: 35510912
[TBL] [Abstract][Full Text] [Related]
19. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
Suzuki K; Iwata A; Iwatsubo T
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
Mullane K; Williams M
Biochem Pharmacol; 2020 Jul; 177():113945. PubMed ID: 32247851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
